ArticleJournal of clinical pathology1995
c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus.
Article in Journal of clinical pathology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.Investigational new drugs · 2012Trial
- Molecules involved in the development of Barrett's esophagus phenotype in chronic eosinophilic esophagitis.American journal of physiology. Gastrointestinal and liver physiology · 2022Article
- HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis.Journal of gastrointestinal oncology · 2014Article
- Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma.World journal of gastroenterology · 2012Article
- Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma.Cancer research · 2012Article
- Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients.World journal of gastrointestinal oncology · 2012Article
- Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- Risk factors for neoplastic progression in Barrett's esophagus.World journal of gastroenterology · 2011Review
- Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics.Investigational new drugs · 2010Article
- Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.International journal of cancer · 2009Article
- In vivo cancer biomarkers of esophageal neoplasia.Cancer biomarkers : section A of Disease markers · 2008Review
- Barrett's oesophagus and adenocarcinoma.World journal of surgical oncology · 2004Article
- Molecular biology of Barrett's adenocarcinoma.Annals of surgery · 2001Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS--To investigate overexpression of the oncoprotein c-erbB-2 in the dysplasia/carcinoma sequence of Barrett's columnar-lined oesophagus (CLO). METHODS--Immunohistochemical staining was performed using the monoclonal antibody NCL-CB-11 on formalin fixed tissue from 31 cases of Barrett's carcinoma, 20 cases of cancer associated dysplastic CLO, seven cases of dysplastic CLO without cancer, and 20 cases of non-dysplastic CLO. Membranous staining was regarded as positive for c-erbB-2 overexpression; cytoplasmic staining was recorded separately as its significance is uncertain. RESULTS--Membranous c-erbB-2 overexpression was observed in eight of 31 (26%) carcinomas and in none of the cases of dysplastic CLO. Variable cytoplasmic staining was seen in four of 31 (13%) tumours and seven of 27 (26%) cases of dysplastic CLO. No staining was observed in non-dysplastic CLO. CONCLUSIONS--C-erbB-2 overexpression is a relatively late event in the development of some Barrett's carcinomas and is unlikely to be involved in the early stages of neoplastic transformation of CLO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.